Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease

Parkinson Disease Clinical Trial

Official title: Botulinum Toxin A (Onabotulinumtoxin A) for Foot Dystonia-associated Pain in Parkinson's Disease: A Randomized, Double-blind Placebo Control Study

Status Recruiting

Clinical Trial Summary

To study the effects of Botulinum toxin type A (BTXA) in the treatment of foot dystonia-associated pain in Parkinson's disease

Clinical Trial Description

Dystonia-associated pain, particularly in the lower limbs is the second most common type of pain in Parkinson's disease (PD). Involuntary muscle contractions that cause slow repetitive movements or abnormal postures are common. The movements may be painful and present in different ways, from just foot inversion or hallux extension to complex forms. They may affect the quality of life of patients in different ways during both ON and OFF periods. Cures for foot dystonia symptoms in PD are not yet available. Yet, improving pain symptoms can improve patients' quality of life. BTXA has been proposed as a safe and useful option for the treatment of PD patients affected by foot dystonia as it could improve symptoms locally without modifying any antiparkinsonian medications. Injected into muscles, BTXA could reduce rigidity, stiffness and improve abnormal postures that may cause foot pain. Recognizing different uses of BTXA will help to understand the symptomatic treatment for each patient in any stage of the disease. The results will help doctors to use new tools to treat foot-dystonia pain in patients with PD. ;

Related Conditions & MeSH terms

• Dystonia
• Dystonia Disorder
• Dystonic Disorders
• Parkinson Disease

• NCT number: NCT04277247
• Study type: Interventional
• Source: University of Calgary
• Contact: Veronica Bruno, MD, MPH
• Phone: 403-220-7572
• Email: veronica.bruno@ucalgary.ca
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: January 12, 2021
• Completion date: December 2022